Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non–Small-Cell Lung Cancer This prospective, cooperative group trial involved 25 institutions over a 3-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results